Population Pharmacokinetics of Necitumumab in Cancer Patients

Abstract

Necitumumab is a second-generation, recombinant, human immunoglobulin G1, epidermal growth factor (EGFR) receptor antibody that specifically blocks the ligand binding site of EGFR. Necitumumab potentially acts by blocking ligand epidermal growth factor (EGF) binding-mediated activation of the EGFR signaling pathway, inhibiting tumor growth, angiogenesis… (More)
DOI: 10.1007/s40262-016-0452-x

8 Figures and Tables

Topics

  • Presentations referencing similar topics